Liege, Belgium, 30 June 2022 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 625,000 new shares today for a total amount of EUR 4,133,933 following the Put Option Notice issued on 13 May, 2022 in the framework of LDA capital commitment agreement entered into April 2020 and extended in April 2022.

Liege, Belgium, 21 June 2022 –07.30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it received subscription commitments from professional, qualified, institutional and other private investors for an aggregate amount of EUR 23.5 million, to subscribe for an aggregate of 3,871,471 new ordinary shares of the Company (being approximately 8.4% of the Company’s outstanding shares) at an issue price of EUR 6.07 per share, representing a 5% discount to the closing share price on Friday 17 June 2022 (the “Private Placement”).

Liege, Belgium, 20 June 2022 – 07:45 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces its intention to proceed with an equity raise for an aggregate minimum amount of EUR 20 million via a private placement of new ordinary shares with certain professional, qualified, institutional and other private investors only (the “Private Placement”).

Liege, Belgium, 20 June 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that Mr. François Fornieri resigned from his non-executive director mandate of the Company. Mr. Fornieri ’s decision, founder and major shareholder of the Company, is based on personal reasons.

Liege, Belgium, 13 June 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received two notifications of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 8 & 9, June 2022.

Liege, Belgium, 06 May 2022 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Glenernie Capital Ltd, with registered offices at Smithson Plaza, 13th Floor, 25 St. James’s Street, London SW1A 1HA, on 3, May 2022. Glenernie Capital has notified Mithra that it has exceeded the statutory 3% threshold on 28, April 2022.

Liege, Belgium, 29 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received two notifications of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 6, April 2022.

Goldman Sachs has notified Mithra on 27, April 2022 that it has exceeded the statutory 3% threshold on 22, April 2022 and then has crossed downwards the statutory 3% threshold on 25, April 2022.

Liege, Belgium, 26 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA) today announces a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège.

Mithra CDMO offers a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals in vials, pre-filled syringes or cartridges.

Liege, Belgium, 20 April 2022 – 07:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to Women’s Health, today announces that Goldman Sachs International (“GSI”) has elected to exercise a call option for an amount of EUR 5,000,000 on 19 April, 2022, according to the terms of the equity funding agreement signed with GSI on February 4, 2022. This call option will result in the issuance of 489,686 shares of the Company.

Liege, Belgium, 19 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the invitation to its ordinary and extraordinary securities holders’ meeting that will be held on Thursday May 19 2022 at 2:00 PM (CEST).

The notice for the General Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.